AI assistant
ABBOTT LABORATORIES — Director's Dealing 2025
Jul 1, 2025
29777_dirs_2025-07-01_11b6ccae-47c1-42c2-9207-e8bb0fd0d87b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2025-06-27
Reporting Person: Cushman Elizabeth C. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-27 | Common shares without par value | A | 3790 | — | Acquired | 25226 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-06-27 | Option (right to buy) | $133.90 | A | 14680 | Acquired | 2035-06-26 | Common Shares (14680) | Direct |
Footnotes
F1: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,893 on June 27, 2026, 4,893 on June 27, 2027, and 4,894 on June 27, 2028.